<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">An Accelerated Development designation relies on the use of surrogate laboratory markers as primary end points that may significantly shorten the study duration, rather than on clinical end points, for drugs intended for use in the treatment of serious or life-threatening illnesses that lack satisfactory treatments.
 <xref rid="bib15" ref-type="bibr">
  <sup>15</sup>
 </xref> Recently approved drugs that were granted an Accelerated Development designation include golodirsen for patients with Duchenne muscular dystrophy, and voxelotor for patients with sickle cell disease. There was a cumulative total of 208 approvals for all products given the Accelerated Development designation by CDER through December 2019.
 <xref rid="bib16" ref-type="bibr">
  <sup>16</sup>
 </xref>
</p>
